Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05021835 · ClinicalTrials.gov registry record · Phase 3
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
A Phase 3 study of Inflammation and Chronic Kidney Disease, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 6,200
- Enrollment target
- 20
- Study locations
NCT05021835 is a Phase 3 study of Inflammation and Chronic Kidney Disease that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 6,200 participants, above the 241-participant average among 132 other Inflammation trials with a reported enrollment target (2473% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05021835, a Phase 3 study of Inflammation and Chronic Kidney Disease, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 6,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine doctors cannot prescribe. Participants will get the study medicine in a pre filled syringe. Participants will need to use the pre filled syringe to inject the study medicine into a skinfold once-monthly. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have blood and urine samples taken at most of the clinic visits. Participants will have their heart examined using sound waves (echocardiography) and electrodes (electrocardiogram). Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
Conditions Studied
Interventions
- DRUG Ziltivekimab B
- DRUG Ziltivekimab C
- DRUG Placebo (Ziltivekimab B)
- DRUG Placebo (Ziltivekimab C)
Study Locations (20)
California
- National Heart Institute Cal - Beverly Hills
- California Inst Of Renal Res - Chula Vista
- California Institute of Renal Research #10 - Chula Vista
- Valley Clinical Trials - Covina
- Valiance Clinical Research - Huntington Park
- Scripps Wht Diab Inst La Jolla - La Jolla
- Balboa Nephro Med Gr Inc LaMes - La Mesa
- First Valley Medical Group - Lancaster
- VA Loma Linda Hlthcr Sys - Loma Linda
- Pacific Clinical Studies - Los Alamitos
- Angel City Research, Inc. - Los Angeles
- North America Research Institute - Lynwood
- Hoag Medical Group - Newport Beach
- Valley Clinical Trials, Inc. - Northridge
Alabama
- Uni of Alabama at Birmingham - Birmingham
- Chambliss Clinical Trials, LLC - Montgomery
Arizona
- Lenzmeier Fam Med CCT Research - Glendale
- Aventiv Research Inc. - Mesa
Arkansas
- Univ of Arkansas Med Sciences - Little Rock
- Unity Health-Searcy Medical Center - Searcy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,200 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2026-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05021835
The ClinicalTrials.gov registry entry for NCT05021835 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 6,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 241-participant average among 132 other Inflammation trials with a reported enrollment target (2473% higher). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 4 interventions - of which Ziltivekimab B is the first listed.
NCT05021835 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05021835 about?
NCT05021835 is a clinical study titled "ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation". This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medic...
What is the current status of trial NCT05021835?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 6,200 participants. The study started on 2021-08-30. Estimated completion is 2026-06-26.
What conditions does trial NCT05021835 study?
This clinical trial studies the following conditions: Inflammation, Chronic Kidney Disease, Cardiovascular Risk.
What interventions are being tested in trial NCT05021835?
The interventions under investigation include: Ziltivekimab B (DRUG), Ziltivekimab C (DRUG), Placebo (Ziltivekimab B) (DRUG), Placebo (Ziltivekimab C) (DRUG).
Who is sponsoring clinical trial NCT05021835?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05021835 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
COMPLETED · Phase 3
-
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
COMPLETED · Phase 3
-
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
COMPLETED · Phase 3
-
A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
COMPLETED · Phase 3
-
Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.